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Maximizing the potential 
of aggressive mouse tumor models 
in preclinical drug testing
M. Tarek Elghetany1,2, Jia‑Min Ho3,4, Lois Hew Shi‑Qi3,4, Sekar Karthik3, Jack M. F. Su1,5,6, 
Qi Lin7,8, YuChen Du7,8, Jianhe Shen1,5, Wing‑Yuk Chow1,5, Ching C. Lau1,5,6,9, 
Adekunle Adesina1,6,10, Angela Major1,2, Anat Erdreich‑Epstein11, Kam‑Man Hui3,12,13, 
Xiao‑Nan Li1,5,6,7,8 & Wan‑Yee Teo1,3,4,5,6,12,13,14*
Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain tumor among infants and 
young children. Two challenges exist for preclinical testing in ATRT. First, genetically quiet, ATRT 
is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor growth—
intercepting the common crossroads in cell cycle progression is a feasible strategy. KIF11 is needed 
for bipolar spindle formation in metaphase. We identified KIF11 as a universal target of all ATRT‑
molecular‑subtypes. Ispinesib, a KIF11‑inhibitor, effectively inhibited tumor proliferation in all seven 
cell lines. A second challenge—a major challenge in preclinical drug testing in‑vivo among aggressive 
tumor models, is the narrow therapeutic window to administer drugs within the limited murine 
lifespan. Our most aggressive ATRT tumor model was lethal in all mice within ~ 1 month of tumor 
implantation. Such short‑surviving mouse models are difficult to employ for preclinical drug testing 
due to the narrow time window to administer drugs. To overcome this time restriction, we developed 
a clinical staging system which allowed physically‑fit mice to continue treatment, in contrast to the 
conventional method of fixed drug‑dose‑duration regimen in preclinical testing which will not be 
feasible in such short‑surviving mouse models. We validated this approach in a second embryonal 
brain tumor, medulloblastoma. This is a clinically relevant, cost‑efficient approach in preclinical testing 
for cancer and non‑cancer disease phenotypes. Widely used preclinical mouse models are not the most 
accurate and lack the aggressive tumor spectrum found within a single tumor type. Mice bearing the 
most aggressive tumor spectrum progress rapidly in the limited murine life‑span, resulting in a narrow 
therapeutic window to administer drugs, and are thus difficult to employ in preclinical testing. Our 
approach overcomes this challenge. We discovered ispinesib is efficacious against two embryonal brain 
tumor types.
Widely used preclinical mouse models are not the most accurate and lack the aggressive tumor spectrum found 
within a single tumor type. Preclinical patient-derived orthotopic xenograft (PDOX) mouse models bearing 
the more aggressive tumor spectrum of a single tumor type, are difficult to employ for drug testing because 
of the short laboratory lifespan. Post-operative recovery after orthotopic brain tumor implantation requires 
10–14  days1. For an aggressive mouse model which survives only 1 month post-tumor-implantation, it leaves 
a narrow time window to administer the drugs and the consequent challenge to achieve sufficient drug doses 
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within the remaining 14–20 days of murine laboratory life-span to induce a tumor resolution. Therefore, the 
current way of conducting preclinical testing, uses less aggressive models within the tumor spectrum of a single 
tumor type, because the animals have a longer murine laboratory life span to allow a feasible time window to 
administer the drug. The main problem with this approach is that, in order to overcome this time window to 
administer the drug, researchers will employ less lethal models that are still representative of the tumor, but with 
a longer median survival. Consequently, aggressive mouse models bearing the greatest burden of aggressiveness 
on the tumor spectrum, are being underutilized in the field of preclinical testing.
Aggressive tumors in PDOX mouse models progress rapidly in the limited murine life-span1,2. Though these 
PDOX models are accurate representation and replicas of the original patients’ disease, they are not used because 
the mice succumb quickly in the disease course and this translates to a narrow therapeutic window to administer 
drugs in preclinical testing. Targeting the most aggressive models within the tumor spectrum is a high prior-
ity to efficiently curate the most effective drugs against a single tumor type. To enable us to use these highly 
aggressive mouse models, we developed a fitness-based staging method to closely monitor the mice health. This 
clinical staging system was necessary to allow physically-fit mice, while carrying the burden of an aggressive 
tumor spectrum, to continue receiving treatment. This fitness-based approach is in contrast to the conventional 
method of preclinical testing. In the conventional approach, all mice have to be administered the same number 
of drug doses over a designated duration. For mice xenografts carrying aggressive tumor spectrum types, they 
become sick rapidly and not all the mice in the cohort will be able to survive or tolerate all the drug doses in this 
conventional fixed drug-dose-duration regimen. Consequently, the healthier mice within the same cohort will 
have to stop treatment at the same time as their sicker counterparts, therefore losing the opportunity of receiving 
further drug treatment to evaluate the drug efficacy. This will render such aggressive mouse models not useful 
and hence not used for preclinical testing. In our current fitness-based approach, we allowed the healthier mice 
to continue on the treatment regimen, and the drug was able to prolong the survival of these animals who were 
fit to receive a longer treatment duration, reflecting a more accurate drug efficacy. This strategy allows aggressive 
mouse xenografts to be utilized for preclinical testing. This is clinically relevant because currently, these PDOX 
mice modelling an accurate aggressive tumor spectrum, are unfortunately not used for drug testing because 
of lifespan limitations. Omitting these aggressive models in preclinical testing further translates to not having 
drugs tested on the most aggressive spectrum of tumor type before moving drugs into clinical trials for patients.
We use an embryonal brain tumor in childhood, atypical teratoid rhabdoid tumor (ATRT) as an example to 
illustrate this  challenge3. Pediatric brain cancer is the leading cause of death in childhood  cancer4,5. ATRT is a rare 
tumor and most frequently affects infants and young children, accounting for 15–20% of all brain tumors in chil-
dren less than 3 years of  age4,5. It is an aggressive brain tumor and historical survival outcome is poor (10–20%, 
5-year survival for patients < 3 years old)6. Standard of care involved surgery, chemotherapy and radiation therapy, 
although none are curative  therapies7. A recently published trial ACNS0333 employing high dose chemotherapy 
and peripheral blood stem cell  rescue8 has improved survival. However, this improved survival was achieved at 
the cost of treatment toxicity with high dose chemotherapy and the subsequent requirement for peripheral blood 
stem cell  rescue8. High rates of treatment failure were observed in this  trial8. More effective drugs are needed for 
ATRT. However, two challenges exist for preclinical testing in ATRT. First, lethal and genetically  quiet9, ATRT 
is a difficult tumor to target molecularly. Tumor cells need to divide to propagate tumor growth—intercepting 
the common crossroads in cell cycle progression is a feasible strategy. KIF11 is needed for formation of bipolar 
spindle in  metaphase10. In this study, we found KIF11 enriched among ATRT tumors, and ispinesib (a KIF11 
inhibitor) was an efficacious agent for this tumor type. A second challenge—a major challenge in preclinical 
drug testing in-vivo among aggressive tumor models, is the narrow therapeutic window within limited murine 
lifespan. We developed a large panel of PDOX ATRT models—the most aggressive PDOX ATRT model has a 
laboratory murine life-span of about 1 month. Post-operative recovery after orthotopic brain tumor implantation 
requires 10–14  days1, which leaves a narrow time window to administer the drugs and the consequent challenge 
to achieve sufficient drug doses within the remaining 14–20 days of murine laboratory life-span of this aggressive 
PDOX model to induce a tumor resolution. Which in this case, renders majority of these aggressive preclinical 
models not useful to be employed in the laboratory. Our fitness-based staging method addressed this problem. 
Our goal is to allow mouse models bearing the most aggressive tumor spectrum to undergo preclinical testing in 
order to identify effective drugs against the most aggressive tumor on the spectrum, to translate to patient care 
and ultimately impact the survival of these patients who are failing current standard therapy.
The problem we address here, is the inability to use these valuable models of the most aggressive spectrum 
for preclinical testing due to the fitness limitations. Our fitness-based staging system is derived to overcome this 
limitation. Mice which are healthier, will be able to tolerate additional drug doses during our preclinical testing 
phase, and by staging their fitness level, we are able to identify and deliver more drug doses to these mice to 
evaluate the true drug efficacy, instead of a shortened drug treatment due to their reduced laboratory lifespan. 
This method enabled us to circumvent the laboratory problem of employing such preclinical models of aggres-
sive tumors, with very short laboratory life span, hence a narrow drug delivery time window. We applied and 
validated the method of fitness-based staging in preclinical testing, the model/s of most aggressive tumor spectrum 
of embryonal brain tumors, and the drug ispinesib in this study.
Results
Targeting the most aggressive PDOX mouse model of ATRT . We have developed a large panel of 
PDOX mouse models using patient tumors and patient-tumor-derived cell lines of ATRT (Figs. 1a, S1A,B). The 
most aggressive ATRT tumor model we have developed was invariably lethal in all mice within ~ 1 month of 
tumor implantation, across multiple reproducible cohorts of mouse xenografts (Figs. 1a, S1B). Drug delivery to 
this tumor model was restricted by the rapid tumor progression time-line.
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Derivation of a clinical staging system for mice health fitness. The conventional method of 
administering a drug for the same fixed drug-dose-duration regimen to every mouse in the entire mouse cohort 
(Fig. 1b,c), will not be a feasible approach for preclinical testing in this aggressive PDOX mouse model with 
a very short laboratory murine life-span of ~ 1  month due to its rapid health deterioration (Fig.  2a,b). Post-
operative recovery after orthotopic brain tumor implantation requires 10–14  days1, which leaves a narrow time 
window to administer the drug and the consequent challenge to achieve sufficient drug doses within the remain-
ing 14–20 days of murine laboratory life-span of this aggressive PDOX model to induce a tumor resolution. 
Ispinesib treatment has to be administered one dose every 4 days for three doses, with the treatment course 
repeated on day 21 (Figs. 2c, 3a). This will equate to only 3 doses of ispinesib within the remaining 14–20 days 
of the murine laboratory life-span after post-operative recovery using the conventional approach of fixed drug-
dose-duration regimen, because the animals will invariably die from the aggressive tumor in 1 month without 
any treatment. It will be possibly unlikely that these 3 doses of an efficacious drug will be able to execute a rapid 
tumor resolution in that short span of time. To enable us to use this aggressive model, we derived a clinical stag-
ing system to closely monitor the health fitness of mice (Fig. 1b,c), concurrently matching their suitability to 
continue on ispinesib treatment regimen, Fig. 1a illustrates the necessity of the fitness score while simultaneously 
using a model representative of the most aggressive state of tumorigenesis.
Paralleling their human disease counterparts, some mice were physically fitter than others during the treat-
ment course (Figs. 1b, 2c, 3a, S2–4), despite uniformly carrying the same tumor burden (same cell dose) from 
orthotopically implanted CHLA-06 ATRT cells (Fig. 2a,b). CHLA-06 was the most aggressive phenotype in our 
panel of ATRT tumor models (Figs. 2a,b, S1A,B). The growth patterns of the same tumor in each mouse can 
differ and result in different neurological deficits, compromising the health status of the mice to different extent. 
Hence some mice can be healthier and others are sicker. This observed fitness spectrum among the mice cohort 
mirrored the varied health fitness status in the clinical care of each individual patient with the same tumor type 
(Fig. 3a). Health fitness and neurological deficits of each patient can vary despite carrying the same brain tumor. 
We staged the mice from Stage 1 to 5 on a daily basis (5 days/week), using clinical categories of 8 parameters 
(Figs. 1c, S3A) including grimace  score11, activity, reaction to handling, body posture, appetite, grooming and 
grip strength. Additional challenge tests (Figs. 1c, S3B) such as grip test (for strength and neurological symptoms) 
and mobilization test (for gait disturbance, agility) will elicit neurological signs.
Our clinical staging system was able to monitor progressive weakness and differentiate it from acute neu-
rological deficits. In creating PDOX brain tumor mouse  models1,2, we found these parameters most useful in 
determining the general health and neurological deficits of mice. Mild neurological signs related to the effects 
of brain tumor, impairing agility, focal weakness and gait disturbance (not affecting animal overall health fitness 
and function) were classified under a separate category of neurological deficits (Figs. 1c, S3A,B). These mild 
deficits were not included in the staging criteria. Progressive or generalized weakness affecting general well-being 
of the animals (using the 8 staging parameters) was included in the staging criteria. We targeted this window of 
Figure 1.  Fitness-based preclinical testing approach employing tumor model of the most aggressive tumor 
spectrum. (a) Widely used preclinical mouse models are not the most accurate and lack the aggressive tumor 
spectrum found within a single tumor type. Our fitness-based approach enabled us to employ the most 
aggressive tumor model for preclinical testing despite the short murine laboratory life-span. (b) Schematic 
illustrating conventional approach of administering drug for the same duration in each mice of the treatment 
cohort, in comparison to our current fitness-adapted approach of clinically staging the mice, matching their 
suitability to continue on ispinesib treatment regimen. (c) Eight staging parameters for general health fitness, 
and challenge tests to elicit neurological signs.
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health fitness in the mice and continued administering ispinesib to the physically-fit animals (between Stage 1 
to 3/4, Figs. 1b, 2c).
Ispinesib treatment using a fitness‑based approach improved animal survival. Strikingly, using 
this clinical staging system to evaluate animal health fitness and determine their suitability to continue drug 
Figure 2.  Ispinesib is a promising therapy for atypical teratoid rhabdoid tumor. (a) Coronal section of magnetic 
resonance imaging (MRI) of an infant with atypical teratoid rhabdoid tumor (ATRT). (b) Top view of cranial 
cavity of different mice implanted with CHLA-06 tumor cells into the right cerebrum (yellow arrows highlight 
the bulging right brain with tumor growth beneath). (c) Treatment timeline in Batch A animals (Treatment 
Group = 5, Control Group = 4). Ispinesib in-vivo dosing was 10 mg/kg administered intraperitoneally every 
4 days for three doses, with the treatment course repeated on day 21. (d) Top view of cranial cavity of mice 
brains in Batch B animals (Treatment Group = 4, Control Group = 3). Brains from ispinesib-treated animals 
(lower panel) were structurally more normal in appearance, in contrast to untreated control animals (upper 
panel) which were distorted by tumor growth and more necrotic in appearance. Similar findings were 
observed in Batch A animals (Fig. S5). (e) Progression-free survival of animals in both Batch A and Batch B 
demonstrating significantly improved survival outcome among ispinesib-treated mice (Log-rank test, Mantel-
Cox method). Solubility of ispinesib was increased using different diluent for reconstitution (“Materials and 
methods”, Batch A: Less soluble. Batch B: More soluble). (f) Overall survival of animals in both Batch A and 
Batch B similarly demonstrating significantly improved survival outcome among ispinesib-treated mice (Log-
rank test, Mantel-Cox method). (g) Hematoxylin and eosin (H&E) staining of formalin-fixed mouse brains 
(ispinesib-treated versus untreated control, Batch A animals). Coronal sections of mouse brains from ispinesib-
treated versus untreated mice showing a tumor mass (black arrows) in the center compressing against normal 
brain tissue. Magnification (×40 and ×100) photomicrographs showing tumor core interfacing with normal 
brain parenchyma in mice brains. Magnification (×600) photomicrographs showing ispinesib-treated tumors 
demonstrating frequent apoptotic bodies (green arrows) but no mitoses (red arrows). In contrast, untreated 
control xenograft tumors demonstrated numerous mitoses (red arrows) and a small number of apoptotic bodies 
(green arrows). (h) H&E Coronal sections of ispinesib-treated versus untreated control (Batch B animals). Black 
arrows indicate tumor. Absence of a visible tumor in mouse which received 7-cycles of ispinesib. Effects were 
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therapy, many of these animals survived to continue receiving additional cycles of ispinesib (Figs. 2c–f, S2). This 
approach significantly prolonged the overall survival of ispinesib-treated mice compared to untreated controls 
(Fig. 2f, Batch A animals, p = 0.0025, Log-rank test), despite small animal numbers. Ispinesib tripled the median 
survival in a repeated batch of animals treated using this fitness-based clinical staging system (Fig. 2f, Batch B 
animals, p = 0.010, Log-rank test). Drug solubility of ispinesib was increased using a different diluent for drug 
reconstitution in Batch B animals (see “Materials and methods”).
Additionally, this clinical staging approach was similarly useful in capturing the progression-free survival 
of mice (survival time from tumor implantation to Stage 3 and 4, Figs. 2e, S4) and demonstrated an improved 
progression-free survival with ispinesib therapy. Among Batch A animals which received 2 cycles of ispinesib 
therapy, one mouse brain did not display obvious tumor burden on serial sectioning with subsequent hematoxylin 
and eosin staining (Fig. S5B). Our fitness-adapted approach of drug administration yielded a multiplier effect 
by enabling more mice to undergo additional cycles of therapy (a treatment group of 4 mice with a net effect 
of 16 mice-treatment-cycles over 7 drug cycles, Figs. 3b, S2B) in contrast to the conventional approach of fixed 
drug-dose-duration regimen, whereby the drug is administered over the same fixed duration for every mouse 
in the treatment cohort (Fig. 1b).
KIF11 is a universal target of all 3 ATRT subtypes. Genetically  quiet9, ATRT is a difficult tumor 
to target molecularly. SMARCB1 mutation is the only consistent mutation that has been more frequently 
Figure 3.  Parallel approach to clinic setting. (a) Our fitness-based staging method leverages the concept that 
mice health status varies despite carrying the same tumor burden. Mice which are healthier, will be able to 
tolerate additional drug doses during our preclinical testing phase, and by staging their fitness level, we are able 
to identify and deliver more drug doses to these mice to evaluate the true drug efficacy, instead of a short drug 
treatment due to their reduced laboratory lifespan. This method enabled us to circumvent a laboratory problem 
employing such preclinical models of aggressive tumors, with very short laboratory life span, hence a narrow 
drug delivery time window. Aggressive brain tumors have rapid clinical progression in patients. Some patients 
become sick more quickly while others remain in overall good health over the treatment course (for illustration 
purpose only, ratio of healthier versus sicker patients varies in different settings). Patients in good overall health 
status will be fit to receive further cycles of therapy. In contrast, sicker patients will not be able to tolerate further 
therapy. (b) Multiplier effect of our fitness-based approach necessitated only 4 PDOX mice in the treatment 
group (example shown here for Batch B experiment), yielding a net 16 mice-cycles of drug treatment. This 
lessened animal numbers for drug testing, hence reducing the cost of preclinical studies. Further, our approach 
enabled healthier mice to receive a higher cumulative drug dose over a longer time period, to evaluate the 
in-vivo drug efficacy against the tumor. A statistically significant improvement in progression-free and overall 
survival was achieved using small animal cohorts, and this effect was replicated (Batch A and Batch B).
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 observed12,13. KIF11 is needed for formation of the bipolar spindle in  metaphase10. KIF11 suppression leads to 
prolonged mitotic arrest and subsequent cell death in  mitosis10. KIF11 inhibitors are in Phase II trials for ovar-
ian  cancer14, and other adult advanced solid  tumors14 such as breast, colorectal, renal, and lung cancers, head 
and neck squamous cell carcinoma, hepatocellular carcinoma and  melanoma15, and Phase I trial for pediatric 
brain and solid  tumors16,17. Ispinesib, a KIF11 inhibitor, has demonstrated effective blood brain barrier penetra-
tion in glioblastoma  xenografts10. We found KIF11 overexpressed in a Discovery Cohort of 10 patient tumors, 
8 tumor cell lines of ATRT, compared to 10 normal brain tumor tissues (Fig. 4a). Importantly, in Validation 
Cohort 1, KIF11 was highly upregulated in a total of 49 patient tumors of all three molecular subtypes of ATRT 
18 (MYC-ATRTs, TYR-ATRTs, and SHH-ATRTs, Fig. 4a,  GSE7067818, Fig. S6A). This makes KIF11 a universal 
target of all ATRT-subtypes. KIF11 was similarly highly expressed in Validation Cohort 2 of 18 patient ATRT 
Figure 4.  KIF11 is a universal target across all ATRT-subtypes and KIF11-targeting with ispinesib inhibited 
proliferation in a panel of 7 ATRT cell lines. KIF11 gene expression in (a) Discovery Cohort of 10 patient 
tumors, 8 patient-derived tumor cell lines, 10 normal brain control tissues (RNA-Seq), Validation Cohort 1 
of patient tumors of three ATRT subtypes—SHH-ATRTs, MYC-ATRTs and TYR-ATRTs (n = 49, Microarray 
Affymetrix U133plus2.0,  GSE7067818), (b) Validation Cohort 2 of 18 patient tumors with long or short survival 
outcome  (GSE2802619, Affymetrix U133plus2.0), and (c) KIF11 relative gene expression in our panel of 7 
patient-derived ATRT cell lines. For Discovery Cohort, KIF11 was highly expressed in patient tumors (Fold 
change 24.4, p < 0.0001, Student T-Test) and tumor cell lines compared to normal brain controls. For Validation 
Cohort 1, patient tumors of all 3 molecular ATRT-subtypes exhibited high KIF11 expression, with SHH-ATRTs 
demonstrating the highest KIF11 expression compared to MYC-ATRTs and TYR-ATRTs (fold change 1.4, 
p = 0.04, Student T-Test). For Validation Cohort 2, KIF11 expression was referenced to GAPDH (housekeeping 
gene), KIF11 was highly expressed in patient groups of both long and short survival outcome (p = 0.4, unpaired 
T-test with Welch’s Correction). (d) Immunohistochemistry of patient tumors from Validation Cohort 3 
similarly demonstrated KIF11 expression, showing Patient Tumor 1 with approximately 10–20% staining (red 
arrows indicate mitoses, green arrows indicate apoptotic bodies). KIF11 protein expression co-localized with 
mitoses. KIF11 (target of ispinesib) was expressed on different cell populations within patient tumor, and not 
restricted to mitoses, indicating ispinesib targeted not only mitoses (actively dividing cells) but also other tumor 
cell populations within the tumor. (e) Targeted KIF11 inhibition: Dose–response effect of ispinesib on 7 ATRT 
cell lines. Values are shown as gradations of green (lowest dose) to purple (highest dose).
7
Vol.:(0123456789)
Scientific Reports |        (2021) 11:11580  | https://doi.org/10.1038/s41598-021-91167-6
www.nature.com/scientificreports/
tumors (Fig. 4b,  GSE2802619). KIF11 expression among tumors from patient groups of long compared to short 
survival outcome (Validation Cohort 2, Fig. 4b) was similarly high (no statistical difference in expression level, 
p = 0.41, unpaired T-test with Welch’s Correction), which was in consonance with our finding of universal high 
KIF11 expression of all 3 molecular ATRT-subtypes (Fig. 4a). In Validation Cohort 3, KIF11 protein was highly 
expressed on patient tumors on immunohistochemistry (Figs. 4d, S6B). KIF11 mRNA and protein were also 
highly expressed in ATRT cell lines (Figs. 4c, S6C).
In‑vitro ATRT cell proliferation inhibited by ispinesib. There are > 20 high affinity, specific small-
molecule KIF11 inhibitors, including  ispinesib10. We found ispinesib an efficacious drug against all 7 ATRT cell 
lines tested (Figs. 4e, S7C one additional ATRT cell line in our collection was very slow-growing and not suitable 
for proliferation assays-ATRT95). These 7 ATRT cell lines were cultured in their respective standard growth 
media which included serum-enriched as well as growth factors-enriched cancer stem cell media (Figs. 4e, S7C). 
Ispinesib was effective against tumor cells in the different growth conditions. This may additionally indicate 
the efficacy of ispinesib against cancer stem cell population of ATRT cells growing as neurospheres in-vitro in 
growth factors-enriched cancer stem cell media (Figs. 4e, S7C). Tumor cell proliferation was effectively inhib-
ited between  IC50 range of 4.5 nM–527 nM on Day 7 for all 7 cell lines (Fig. S7C). Ispinesib concentration of 
5 nM–1.25 µM demonstrated sustained time-dependent killing-effect on all 7 cell lines over 13 days (Fig. S7C).
ATRT cells undergo ispinesib‑induced cell cycle arrest and apoptosis. Ispinesib at ≤ 10  nM is 
highly effective against 2 most tumorigenic cell lines (CHLA-06, BT-37), inducing G2/M arrest (Fig. 5a) and 
causing apoptotic cell death (61.8% early and late apoptotic cells in BT-37 cells at 48 h, 51.6% in CHLA-06 cells 
at 72 h of ispinesib treatment, Fig. 5b). This apoptotic cell death effect was consistently observed with ispinesib 
treatment when tested on additional ATRT cell lines (Fig. S7). On hoechst-staining under fluorescent micros-
copy, ispinesib-treated BT-37 and CHLA-06 cells at 24 h (Figs. 5c, S6C, S8) demonstrated significant increase in 
micronuclei. Significant increase in apoptotic cells was also observed in ispinesib-treated BT-37 cells.
Immunoblotting (Figs. 5d, S6C,E) indicated diverse effects of ispinesib through a variety of cell death mecha-
nisms on our collective panel of ATRT cell lines (CHLA-06, BT-37, CHLA-05). DNA damage was indicated by an 
increase in histone H2A.X in ispinesib-treated CHLA-06, CHLA-05 and BT-37 cells. KIF11 protein expression 
was enriched in CHLA-06, CHLA-05 and BT-37 cells after 24 h of ispinesib treatment. In-vivo, KIF11 protein 
enrichment was similarly observed after 1 cycle of ispinesib treatment (Fig. 5e). KIF11 can therefore, be a stable 
drug target. Ispinesib treatment upregulated caspase-3 and c-PARP protein expression in CHLA-06, CHLA-05 
and BT-37 cells (Fig. 5d), supporting ispinesib-induced apoptosis.
We further confirmed the findings of ispinesib-induced apoptotic cell death in-vivo. Untreated CHLA-06 
xenograft tumors (Fig. 2g) demonstrated numerous mitotic figures and few apoptotic cells, while ispinesib-treated 
xenograft tumors were almost devoid of mitotic figures and had frequent apoptotic cells. Effects were tumor-spe-
cific; surrounding mouse brain parenchyma remained healthy with normal appearance, after 7 cycles of ispinesib 
treatment (Fig. 2g,h). In patient tumors (Patient 1, Figs. 4d, S6B), we observed KIF11 expression co-localized 
with mitotic cells. Mitoses from our ATRT tumor model (Fig. 2g) were consistent with the representation of the 
typical distribution in the average patient tumor (Fig. 4d). KIF11 (target of ispinesib) was expressed on different 
cell populations within PDOX tumor and patient tumor (Fig. 4d), and not restricted to mitoses, indicating ispi-
nesib targeted not only mitoses (actively dividing cells) but also other tumor cell populations within the tumor. 
KIF11 expression on actively dividing tumor cells, presented KIF11 as an attractive target for anti-cancer drugs. 
Taken together, ispinesib was an efficacious therapeutic agent against ATRT in-vitro (resulting in growth arrest 
and death of tumor cells) and in-vivo (leading to apoptotic tumor cell death and improved animal survival).
Ispinesib is efficacious in a 2nd pediatric embryonal brain tumor model. We observed KIF11 (tar-
get of ispinesib) expressed on some of our PDOX models of medulloblastoma (MB), another type of embryonal 
brain  tumor4,5. MB is the most common malignant brain tumor in  children4,5. In this second model of pediatric 
embryonal brain tumor, immunohistochemical staining of some MB PDOX models with KIF11 antibody dem-
onstrated KIF11 expression co-localized with mitotic figures, illustrated by Model ICb-1572 (Fig. 6a). KIF11 
was again expressed on different cell populations within PDOX tumor (Fig. 6a), and not restricted to mitoses, 
indicating ispinesib targeted not only mitoses (actively dividing cells) but also other tumor cell populations 
within the tumor. Cytoplasmic staining of KIF11 was observed on 5–10% of cells in Model ICb-1572, including 
mitotic figures (Fig. 6a, Magnification 400×). Normal brain parenchyma was devoid of KIF11 expression, inter-
facing with tumor core densely packed with tumor cells. Tumor core was enriched with actively dividing cells 
marked by  KIF11+ mitotic figures (Fig. 6a), a good target for ispinesib. Pediatric MB is molecularly classified into 
4 molecular subtypes: sonic-hedgehog (SHH)-activated MB, Wingless (WNT)-activated, and less characterized 
Group 3 and 4 subtypes (Fig. 6b)20,21. Group 3 and 4 MBs are most the aggressive subtypes with the worst sur-
vival  outcome22,23. PDOX Model ICb-1572 is Group 3 subtype, characterized by genomic profiling (Fig. 6b–d)24. 
Our PDOX models have been characterized and recapitulated patient  tumors1,24. Ispinesib effectively inhibited 
cancer stem cell enriched 3D-neurospheres derived from aggressive Group 3 PDOX MB (Model ICb-1572) over 
7-day in-vitro treatment (Fig. 6e). Monolayer tumor cells of Model ICb-1572 demonstrated similar susceptibil-
ity (Fig. 6e). In-vivo, ispinesib significantly improved the overall survival (p = 0.0003, Log-rank test) of mice 
bearing Group 3 subtype MB (Model ICb-1572, Treatment Group = 7, Control Group = 6, Fig. 6f). We employed 
the same clinical staging system (Fig. 1b,c) to evaluate animal health fitness and determine their suitability to 
continue drug therapy. Brains, particularly the tumor-bearing cerebellum from ispinesib-treated animals (right 
panel, Fig. 6g) were structurally more normal in appearance, in contrast to untreated control animals (left panel, 
Fig. 6g) where the cerebellums were distorted by tumor growth, and were soft and necrotic in appearance.
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Discussion
Creation of PDOX models is a lengthy and costly  process25. To derive sufficient statistical significance for survival 
analyses, large numbers of PDOX mice are required for preclinical testing of each drug. This further escalates the 
cost of in-vivo preclinical drug testing for each compound, using PDOX models. Nonetheless, PDOX models 
are still the preferred cancer model over culture-based spheroids or slice  cultures25. In 2016, the US National 
Cancer Institute (NCI) has decided to stop screening most drugs using the NCI-60, its panel of 60 human cancer 
cell lines grown in culture, after more than 25 years of heavy use by worldwide researchers, and is developing 
PDOX models that better mimic the human counterpart. Aggressive models will curate the most efficacious 
drugs with strong preclinical data to translate into clinical trials for patients. However, these xenografts are 
under-utilized because a major limitation of such aggressive tumor models exists—the narrow time window for 
drug administration to gather statistically significant survival data in murine models with a limited laboratory 
life-span. Consequently, these aggressive tumor models are not the intuitive choice for preclinical drug testing.
Our current approach of staging the health fitness status in the mice, circumvents this problem and taps 
into the valuable resource of aggressive tumor models for therapeutic testing (Fig. S9, Schematic). Adopting 
this clinical staging system offered a unique opportunity to study drug efficacy in the most aggressive tumor 
models and unexpectedly decreased the cost of testing in PDOX models by using lesser animal numbers. Our 
fitness-adapted approach of drug administration yielded a multiplier effect by enabling more mice to undergo 
additional cycles of therapy in contrast to the conventional approach of fixed drug-dose-duration regimen. In 
the conventional approach, the drug is administered for the same fixed duration for every mouse in the treat-
ment cohort which will not be feasible in aggressive PDOX mouse models with a very short laboratory murine 
life-span, with survival of ~ 1 month, due to their rapid health deterioration. Our strategy also enabled a higher 
total cumulative drug dose to be administered to some mice which were fit to receive more drug cycles, therefore 
maximizing the drug efficacy.
Preclinical studies and Phases I-III clinical trials are time consuming. A major factor contributing to clinical 
trial failure has been attributed to patient selection, as a therapeutic agent may only be effective in a subset of 
patients with the same  cancer25. Targeting PDOX model of the most aggressive spectrum within each tumor type, 
which is our current approach, will strengthen the preclinical data and ensure that the drug brought to clinical 
trial will be efficacious against the most aggressive subset. As a collaborative group, our PDOX models have been 
characterized and recapitulate patient  tumors1,2,24, and are widely used by the neurooncology community, and 
have led to subsequent clinical trials. Ispinesib is already in Phase II trials for many adult  cancers14,15. Pharma-
cokinetic data for pediatric dosing of ispinesib is available from a prior small Phase I trial which included a mix 
of 24 pediatric recurrent/refractory solid  tumors16. The available pharmacokinetic data will facilitate a pediatric 
Phase II trial for the two embryonal brain tumor types (ATRT and MB) evaluated for in-vivo efficacy in our 
study. Our preclinical data will be crucial for driving FDA approval of ispinesib for ATRT and MB.
Disadvantages of our approach include longer time required to perform daily clinical staging, more in-depth 
training and time invested in training research staff to perform accurate staging through observation, clinical 
examination and charting. Some may argue that using this fitness-based approach, different mice in the same 
treatment cohort will be administered different total drug doses, instead of a fixed total dose across all animals 
in the conventional approach. On the contrary, we would argue that our current approach provides more accu-
rate data on the drug. During cancer treatment, patients differ in health fitness and their ability to tolerate drug 
treatment. Our approach recapitulates the varied clinical setting among patients with aggressive tumors, who will 
unavoidably receive adjustment in doses and treatment duration, particularly during clinical trial phase. Lastly, 
immunosuppressed mice used for xenograft modelling are highly vulnerable to infections and succumb quickly 
from common side effects of drugs, such as gastrointestinal effects and diarrhea. This can further increase animal 
number requirements and cost of preclinical testing in mice. Our approach of clinically staging the health status 
of mice will allow us to capture the variation in their health fitness and avoid drug administration in animals 
with poorer fitness, allowing recovery before proceeding with further drug doses. This will ensure that the animal 
survival will more accurately reflect the drug-on-tumor effects, instead of confounders such as drug side effects on 
immunocompromised mice leading to infections and thus shortening the animal life-span. Consequently, these 
animals can recover and continue on to receive a longer course of treatment to evaluate the highest drug efficacy.
Figure 5.  Functionally defined cell death mechanisms in ispinesib therapy. (a) Cell cycle analysis of CHLA-06 
and BT-37 treated with ispinesib 4.69 nM (Day 4  IC50 dose) and 10 nM (Day 4  IC90 dose) respectively for 24 h. 
(b) Flow cytometry analysis for apoptotic cell death (Annexin  V+  PI−) in BT-37 treated with ispinesib (10 nM) 
for 24 h and 48 h. Flow cytometry analysis for apoptotic cell death (Annexin  V+  PI−) in CHLA-06 treated with 
ispinesib (4.6 nM) for 48 h and 72 h. (c) Hoechst staining of cell nuclei, BT-37 and CHLA-06 treated with 
10 nM and 4.69 nM ispinesib respectively for 24 h. Ispinesib-treated BT-37 cells (average apoptotic cells = 2/
hpf, average micronuclei = 4/hpf) demonstrated tenfold increase in apoptotic cells (p = 0.002, unpaired T-Test) 
and eightfold increase in micronuclei (p = 0.007, unpaired T-Test) compared to DMSO vehicle control treated 
cells (average apoptotic cells = 0.2/hpf, average micronuclei = 0.5/hpf). Ispinesib-treated CHLA-06 cells (average 
micronuclei = 1.28/hpf) demonstrated tenfold increase in micronuclei (p = 0.0122, unpaired T-Test) compared 
to DMSO vehicle control treated cells (average micronuclei = 0.117/hpf). Micronuclei (red circle) and condensed 
apoptotic nuclei (green circle) can be seen after ispinesib treatment. (d) p-Histone H2A.X was increased with 
24 h and 48 h-ispinesib treatment in CHLA-06 and BT-37 cells, indicative of ispinesib inducing DNA-damage. 
c-caspase 3 and c-PARP were also increased with ispinesib treatment, supporting activation of intrinsic 
apoptosis pathway. (e) Immunohistochemistry demonstrates that in-vivo, tumor cells were enriched in KIF11 
protein expression within tumor core of CHLA-06 xenograft (after 1 cycle of ispinesib treatment) in contrast to 
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Figure 6.  Ispinesib is efficacious against a second model of pediatric embryonal brain tumor. (a) KIF11 (target 
of ispinesib) was expressed on our PDOX models of medulloblastoma (MB), another type of embryonal brain 
tumor. MB is the most common malignant brain tumor in children. Immunohistochemical staining of several 
of our MB PDOX models with KIF11 antibody demonstrated KIF11 expression co-localized with mitotic 
figures, shown here in Model ICb-1572. KIF11 was expressed on different cell populations within PDOX tumor 
(shown here in brown staining), and not restricted to mitoses, indicating ispinesib targeted not only mitoses 
(actively dividing cells) but also other tumor cell populations within the tumor. Cytoplasmic staining of KIF11 
was observed on 5–10% of cells, including mitotic figures (red arrows), ×400. Normal brain parenchyma was 
devoid of KIF11 expression, interfacing with tumor core densely packed with tumor cells. Actively dividing 
cells were marked by  KIF11+ mitotic figures—a good target for ispinesib. (b) Pediatric MB is molecularly 
classified into 4 molecular subtypes: sonic-hedgehog (SHH)-activated MB, Wingless (WNT)-activated, and less 
characterized Group 3 and 4  subtypes20,21. Group 3 and 4 MBs are the most aggressive subtypes and Group 3 
MBs have the worst survival  outcome22,23. PDOX Model ICb-1572 is Group 3  subtype24. (c) Hematoxylin & 
eosin stains showing a large xenograft MB tumor of Group 3 subtype (Model ICb-1572), occupying almost the 
entire mouse cerebellum. Histological appearance (40X) of xenograft tumor was consistent with densely packed, 
small round blue cell typical of MB. Our panel of xenograft tumors recapitulate morphologic, histological 
and immunohistochemical features of matched patient original  tumors1. Animal survival was monitored up 
to Passage IV-IX for Model ICb-1572. Log rank analysis of animal survival times of ICb-1572 MB during 
serial sub-transplantation of retrieved xenograft cells from cryopreservation (Passage III to VIII is shown 
here using Passage I as reference). Survival days were consistent and maintained within and across passages 
in mice. (d) Patient characteristics of Model ICb1572. (e) Tumor proliferation activity—ispinesib against 
in-vitro 3D-Neurosphere cultures of Model ICb1572. Cancer stem cell enriched neurospheres derived from 
aggressive Group 3 subtype (Model ICb-1572) demonstrated susceptibility to 7-day in-vitro treatment with 
ispinesib. Monolayer tumor cells of Model ICb-1572 demonstrated similar susceptibility. Area under curve 
(AUC) > 0.7 was the significant cut-off. (f) Top view of cranial cavity of mice brains (Treatment Group = 7, 
Control Group = 6). We employed the clinical staging system to evaluate animal health fitness and determine 
their suitability to continue ispinesib therapy. Brains, particularly the tumor-bearing cerebellum (yellow arrows), 
from ispinesib-treated animals (right panel) were structurally more normal in appearance, in contrast to 
untreated control animals (left panel) where the cerebellums were distorted by tumor growth, soft and necrotic 
in appearance. (g) Overall survival and progression survival (Stage 3) of animals was significantly improved with 
ispinesib treatment (p = 0.0003, p = 0.03 respectively, Log-rank test).
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PDOX models that accurately recapitulate the biology of corresponding patient tumors, will replicate the clini-
cal course and survival patterns of the patient  tumors1,2,24,25. Genomic profiling has subclassified each brain tumor 
type into different molecular subtypes, for example MB has been classified into 4 major molecular subtypes—
SHH-subtype, WNT-subtype, Group 3 and Group 4  subtypes20,21. Group 3 and Group 4 are the most aggressive 
subtypes with the worst prognosis and survival outcome among  patients22,23. Capability to use aggressive PDOX 
models for preclinical testing should be valued as an added advantage and an additional tool for preclinical test-
ing. Our fitness-based approach of preclinical testing provides this added capability. Our fitness-based staging 
approach is feasible in both less aggressive models with longer laboratory life-span (data not shown), and more 
aggressive models with shorter laboratory life-span. We performed this fitness-based staging for up to 400–500 
brain-tumor-bearing mice over the past few years. This provides further validation that the method, the model/s 
and the drug, are robust.
Majority of patients with ATRT are young children or infants < 3 years of  age6. The standard of care, histori-
cally for this young age group is maximal tumor resection where safely  possible7 and chemotherapy. Radiation 
therapy is often avoided in this young age group to avoid long term neurocognitive  sequelae7. Outcome is  dismal6 
for this age group with the restriction of radiation therapy use. A recently published clinical trial ACNS0333 
employing high dose chemotherapy and peripheral blood stem cell  rescue8 has remarkably improved the 4-year 
event-free survival to 37% compared to historical cohort of 6.4%. However, this improved survival was achieved 
at the cost of treatment toxicity of high dose chemotherapy and the subsequent requirement for peripheral 
blood stem cell  rescue8. Further, 91% of patients experienced treatment failures, which occurred by 2 years from 
 enrollment8. More effective drugs are needed for ATRT. Ispinesib thus offers a potential promising therapeutic 
adjuvant post-surgery, particularly in the setting of minimal residual tumor, for tumor control and to improve 
patient survival. We tested ispinesib on 7 ATRT cell lines, with different growth rates—Ispinesib was effective 
in all 7 ATRT cell lines with different growth rates. This serves as additional support that ispinesib was a robust 
drug, efficacious among ATRT cells with different growth rates. Ispinesib was similarly efficacious in our second 
PDOX model of pediatric embryonal brain tumor—aggressive Group 3 MB. The gene target of ispinesib, KIF11, 
co-localized with mitotic figures in both ATRT and MB, which makes this drug a good target against actively 
dividing tumor cells. Additionally, KIF11 was expressed on different cell populations within PDOX tumor and 
patient tumor of both types of embryonal brain tumors (ATRT and MB), and not restricted to mitoses, indicat-
ing ispinesib targeted not only mitoses (actively dividing cells) but also other tumor cell populations within the 
tumor.
Finally, our approach in preclinical testing offers a threefold benefit: first, cost reduction in preclinical testing. 
Second, we tap into the valuable resource of aggressive tumor models for therapeutic testing, to curate the most 
efficacious drugs with robust preclinical strength to translate into clinical trials. Third, because aggressive tumors 
progress quickly such as our current CHLA-06 tumor model and ICb-1572 Group 3 MB model, the mice invari-
ably die in a month—it provides in-vivo data in a short time-frame as any survival benefit prolonging murine 
lifespan will be rapidly evident in the laboratory.
Materials and methods
Ethics approval. All primary tumor specimens were obtained through an Institutional Review Board 
approved protocol from patients treated at the Texas Children’s Hospital (Houston, Texas, USA) after informed 
consent was signed. Paraffin sections from resected ATRTs were used for immunhistochemistry. This study was 
conducted in accordance and approval by Centralized Institutional Review Board, SingHealth Duke-NUS Aca-
demic Medical Center, Singapore. Animal studies were conducted in accordance and approval from Institutional 
Animal Care and Use Committee, SingHealth Duke-NUS Academic Medical Center, Singapore.
Immunohistochemistry. Immunolocalization of KIF11/EG5 protein was performed on Validation Cohort 
3 of formalin-fixed paraffin-embedded primary pediatric ATRT samples using a commercially available KIF11/
Eg5 monoclonal antibody. The Leica BOND-III automated IHC Instrument (Leica Biosystems). The stained sec-
tions were reviewed by a pathologist blinded to data associated with the investigation.
Primary tumor specimens. Fresh tumor specimens were snap frozen in liquid nitrogen and stored at 
− 80 °C. A total of 10 primary pediatric ATRTs collected between 1994 and 2014, and a panel of 8 patient-derived 
ATRT cell lines from international collaborating institutions, were extracted for RNA, used for RNA-Seq and 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) in this study. The patient tumor sam-
ples were treatment-naïve and obtained at diagnosis, prior to treatment initiation.
RNA‑Seq, gene expression microarray and classification of SHH‑ATRTs, MYC‑ATRTs and 
TYR‑ATRTs. RNA was extracted from fresh frozen patient ATRT tumor samples and a panel of 8 patient-
derived ATRT cell lines using TRIzol (Invitrogen, Carlsbad, CA). Expression profiles of 10 primary human 
ATRTs, 8 ATRT cell lines and 10 control brain tissue RNA were generated using RNA Seq according to manufac-
turer’s protocol (conducted by BGI Sequencing) for the Discovery Cohort. For Validation Cohort 1, CEL files of 
49 patient ATRT tumors profiled using Affymetrix HG-U133plus2.0 gene chips (Affymetrix Inc. Santa Barbara, 
USA), were downloaded from  GSE7067818. Subtype identity of each patient tumor was determined by subtype-
specific gene sets  published18. Primary human ATRTs were classified into molecular subtypes, Sonic-hedgehog 
(SHH)-ATRTs, MYC-ATRTs and TYR-ATRTs18. For Validation Cohort 2, CEL files of 18 patient ATRT tumors 
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Transcriptome sequencing (RNA‑Seq). Genome wide transcriptome analysis was performed for 28 
samples (10 primary human ATRTs, 8 ATRT cell lines and 10 control brain tissue RNA) using Illumina Hiseq 
platform. Total RNA was extracted and treated with DNase I and mRNA were isolated using Oligo(dT) and 
are fragmented using the fragmentation buffer and the cDNA is synthesized. The short fragments are purified 
and resolved with EB buffer and added with single nucleotide A (adenine). The adapter sequences were added 
to the short fragments and the suitable fragments are selected for the PCR amplification. For QA/QC of the 
sample libraries we have used Agilent 2100 Bioanaylzer and ABI StepOnePlus Real-Time PCR System. The 
library is sequenced using Illumina HiSeq 4000. Paired end 2 × 100 base pair reads were generated on a HiSeq 
system (Illumina, San Diego, CA) and on average 8.96 Gb bases of reads was generated from each sample. The 
low-quality sequencing reads were removed before performing downstream analysis and the clean reads were 
mapped to hg19 reference genome using HISAT and on average 85.42% reads are mapped to the reference 
genome. After mapping sequenced reads to reference genome, the transcripts were reconstructed. A total of 
23,672 coding genes were identified.
RNA‑seq data analysis. For gene expression analysis, the clean reads were mapped to reference genome 
using Bowtie2 (v2.2.5). Gene expression levels were calculated with RSEM (v1.2.12). To identify genes that were 
differentially expressed between patient tumors and normal brain controls, we performed ANOVA analysis 
using Partek Genome Suite. Total of 7313 genes were differentially expressed between 10 patient tumors and 10 
normal brain controls with the cut-off of p-value with FDR < 0.05 and |FC > 2|. Student T-Test was used to com-
pare KIF11 gene expression between patient tumors and control brain tissues (24.4-fold higher among patient 
tumors (p < 0.0001).
Microarray data analysis. We downloaded the gene expression microarray data of 49 ATRT patient 
tumors from GEO (Accession ID:  GSE7067818). Metadata containing tumor subtype identity for the 49 ATRT 
samples were downloaded. ATRT patient samples of three subtypes (MYC-ATRT, SHH-ATRT and TYR-ATRT) 
were identified  previously18. Of 49 patient tumors, 15 tumors were MYC-subtype, 16 tumors were SHH-subtype 
and 18 tumors were TYR-subtype. The 49 raw CEL files were imported into Partek Genome Suite. RMA back-
ground correction and quantile normalization were performed. The gene expression values were log2 trans-
formed and used for downstream gene expression analysis.
Quantitative real‑time polymerase chain reaction. Total RNA was extracted from cultured cells from 
7 ATRT cell lines, using TRIzol Reagent (Invitrogen, US) and reverse transcription was performed using high-
capacity RNA-to-cDNA kit (Applied Biosystem, US), according to manufacturer’s protocol. Real-time PCR was 
performed on C1000 Thermal Cycler (Bio-rad Laboratories, US) using SensiFAST Probe No-ROX kit (Bioline, 
UK). Each sample was loaded in triplicates. SYBR-green primers used for the reactions were KIF11 (H_KIF11_1, 
Sigma-Aldrich, Germany) and housekeeping gene, GAPDH (H_GAPDH_1, Sigma-Aldrich, Germany). PCR 
was performed with initial polymerase activation at 95  °C for 2  min, followed by 40 cycles of amplification 
(denaturation at 95 °C for 5 s, annealing at 65 °C for 10 s and extension at 72 for 20 s). The relative expression for 
each mRNA was calculated by formula of 2−Ct.
Proliferation assays. Tumor cells were seeded in 96-well plates in quadruplicates for each treatment con-
dition. Ispinesib was added at the specified concentration range (CHLA-04-ATRT, CHLA-05-ATRT, CHLA-
06-ATRT and BT-37 between 0.625 and 20  nM; BT-12, CHLA-266, CHLA-02-ATRT between 0.01 and 100 
μM). Cell proliferation was determined using Cell Counting Kit-8. Optical density (OD) was measured using 
Promega GloMax-Multi Detection System.
Flow cytometry. Tumor cells were treated in culture with ispinesib at the indicated concentrations to detect 
apoptosis. At each timepoint, cells were harvested and stained with Annexin V-FITC and PI according to manu-
facturer’s instructions (BD Annexin V FITC Apoptosis Detection Kit I, USA). Stained cells were then analyzed 
by flow cytometry (BD FACS Canto™ II, US) at the excitation wavelength of 488 nM (FITC) and 595 nM (PI). 
Cultured cells were treated with ispinesib at the indicated concentration to study the cell cycle changes. Cells 
were harvested and fixed with absolute ethanol. Fixed cells were stained with PI/RNase A mastermix (PI and 
RNase A) prior to analysis by flow cytometry (BD FACS Canto™ II, US).
Hoechst staining. Tumor cells treated with either DMSO-vehicle or ispinesib were harvested and washed 
with PBS prior to fixation using 4% paraformaldehyde. Cells were stained with Hoechst 33258 (Invitrogen, US) 
in PBS. Slides were prepared in a pair: DMSO-vehicle treated and ispinesib-treated. Slide pairs were prepared 
in triplicates. Stained cells were observed under a fluorescence microscope (Nikon Eclipse 80i, US). For each 
slide, 20 high power fields (hpf) were captured under fluorescent microscopy. Photomicrographs of each hpf in 
bright field and corresponding UV field were taken. Cells with abnormal nuclear morphology (either apoptotic/
condensed nuclei, Fig. S8) in 20 hpf were manually counted. Apoptotic cells were represented by a solid, clearly-
demarcated rounded nucleus, while micronuclei appeared as a cluster of small, fragmented nuclei. Apoptotic 
cells with surrounding micronuclei were counted as micronuclei (to avoid double counting). The average num-
ber of cells per hpf was computed. The mean and standard deviations were represented on bar graphs (Fig. 5c) 
and the data analyzed using parametric, unpaired t-test.
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Western blotting. Protein extracts were obtained by suspending cells in RIPA buffer containing protease and 
phosphatase inhibitors (Sigma-Aldrich, US). Protein samples were first denatured with 5% β-mercaptoethanol 
in Laemmli’s buffer at 95 °C. Equal amount of denatured proteins was run on NuPAGE 4–12% Bis–Tris Protein 
Gel and transferred onto a membrane. The membranes were blocked with 5% milk and incubated with different 
primary antibodies respectively at 4 °C. Membranes were washed in TBS-T (TBS containing Tween-20) prior to 
incubation with respective secondary antibodies. Membranes were developed using Pierce ECL Western Blot-
ting substrate (Thermo Scientific, US) and chemiluminescence signals were detected using ChemiDoc Imaging 
System, Bio-Rad Laboratories, Inc., US).
Orthotopic implantation of patient‑derived tumor cells into mouse brains. Rag2/Severe com-
bined immune deficiency (SCID) mice were bred and housed in a pathogen-free facility. All animal experiments 
were conducted in accordance to protocol approved by the Institutional Animal Care and Use Committee at 
SingHealth Duke-NUS Academic Medical Center, Singapore. Surgical implantation of tumor cells (1 ×  105) into 
mouse cerebrum was performed using our method previously  described1,2.
The general recommendations in ARRIVE guidelines 2.0 (https:// arriv eguid elines. org/) were followed in 
our study. Our sample size was small. We did not use any method to generate the randomisation sequence. The 
animals were randomly assigned into treatment versus control groups to have approximately equal number of 
animals per group. We have recently published that gender does not statistically affect treatment  outcome26, and 
both genders were included in our study. Our animals were housed in the same location in side-by-side cages and 
managed in a standardized maintenance protocol by the animal unit and our team to minimize any confound-
ing effects, we did not employ any special strategy to minimize other confounders. Treatment was delivered to 
animals assigned in treatment group, cage-by-cage. Blinding was not possible as we have a small team of 2–3 
individuals working with the animals and we are all involved at various stages and day-to-day processes of the 
animal work. For ATRT tumor, the in-vivo experiment was repeated across 2 batches, and in conjunction with 
MB tumor, a total of 3 separate batches comprising of various litters were used, minimizing bias from the same 
litter effect. Additional animal data was included in our supplementary material. We have previously published 
using this animal protocol, and is not otherwise deposited in any repository/registry.
Intraperitoneal drug administration. Ispinesib was dissolved in a solution of dimethyl sulfoxide, water 
for Batch A animals. To improve the solubility, ispinesib was dissolved in a solution of Cremophor EL, dimethyl 
sulfoxide, water in the subsequent Batch B animals. For both Batch A and B, ispinesib was administered intra-
peritoneally every 4 days for three doses, with the treatment course repeated on day 21. The dose of ispinesib 
was 10 mg/kg. The mice were given up to seven cycles of treatment, depending on their health fitness suitability 
determined by our clinical staging system. There were 9 animals (5 treated, 4 control) in Batch A and 7 animals 
(4 treated, 3 control) in Batch B.
Clinical staging system to monitor mice fitness. We derived a clinical staging system to closely moni-
tor the health fitness of mice, concurrently matching their suitability to continue on ispinesib treatment regi-
men (Figs. 1b,c, S3). Paralleling their human disease counterparts, some mice were physically fitter than others 
during the treatment course (Figs. 1b, 3a, S2–4), despite uniformly carrying the same tumor burden (Cell dose 
1 ×  105) from orthotopically implanted ATRT cells (CHLA-06-ATRT, Fig. 1). We staged the mice from Stage 
1 to 5 on a daily basis (5 days/week), using clinical categories of 8 parameters (Figs. 1c, S3) including activity, 
eating, grooming and grimace  score11. Additional challenge tests (Fig. 1c) such as grip test (for strength and 
neurological symptoms) and mobilization test (for gait disturbance, agility) will elicit neurological signs. Mild 
neurological signs related to the effects of brain tumor, impairing agility, muscle weakness and gait disturbance 
(not affecting animal overall health fitness and function) were classified under a separate category of neuro-
logical deficits (Figs. 1c, S3A,B). Mild deficits not affecting animal overall health fitness and function were not 
included in the staging criteria. Progressive or generalized weakness affecting general well-being of the animals 
(using the 8 staging parameters) was included in the staging criteria. We targeted this window of health fitness 
in the mice and continued administering ispinesib to the healthier animals (between Stage 1 to 3/4, Figs. 1b, 3).
Statistical analyses of animal survival. The survival of each mouse was taken to be the number of days 
from the date of tumor implantation to the date of death (overall survival) or date of progression to Stage 3 or 4, 
where event = 1 and censored subject = 0. Data were censored for mice that were alive at the time of analysis. All 
Kaplan–Meier survival curves were plotted using GraphPad Prism 8.1.0 and the survival analysis was performed 
using Log-rank (Mantel-Cox) test.
Data availability
The Cancer Genome Atlas (TCGA) Research Network; Accession codes-GSE42670, GSE19578, GSE74187. 
Non-commercial cell lines and materials used in this project were obtained through an MTA with international 
collaborating institutions.
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A. Establishment of a large panel of patient-derived orthotopic xenograft (PDOX) mouse models
using patient tumors and patient-tumor-derived cell lines of ATRT. CHLA-06 was the most aggressive














CHLA-02 Yes No 2 early animal deaths (Day 4, Day 
21) likely non-tumor related
197 days 1
CHLA-04 Yes No NA 243 days 5
CHLA-05 Yes Yes NA 151 days 4
CHLA-06 Yes Yes Highly aggressive. Invariably lethal 
in all animals within 1 month of 
tumor implantation
22 days 14
CHLA-266 Yes No NA 235 days 5
BT-12 Yes No NA 77 days 5
BT-37 Yes Yes Median survival longer than CHLA-
06 model
63.5 days 4













Yes Yes Data not shown; Median survival 
longer than CHLA-06 model
IC-
1218ATRT
Yes Yes Data not shown; Median survival 
longer than CHLA-06 model
ICb-
1355ATRT
Yes Yes Data not shown; Median survival 
longer than CHLA-06 model
ICb-
5108ATRT
Yes Yes Data not shown; Median survival 




Yes Yes Data not shown; Median survival 
longer than CHLA-06 model
Fig. S1
B. Survival curves of different PDOX tumor models studied. Upper Panel: Survival curves of multiple
cohorts (different experimental batches) of PDOX mouse models bearing CHLA-06 tumor cells (Cell
dose 1X10-5) demonstrating uniform aggressive behaviour of this ATRT tumor model. This tumor model
was invariably lethal in all mice within ~1 month of tumor implantation across multiple, reproducible
cohorts of mouse xenografts. Lower Panel: Survival curves of other PDOX tumor models created with
various patient-derived ATRT cell lines using the same orthotopic implantation technique (see
Methods).
B. Survival curves for multiple batches of CHLA-06
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PDOX Tumor Model using CHLA-06

























PDOX Tumor Models using various Patient-derived ATRT Cell Lines
*CHLA-02: 2 early 
animal deaths (Day 4, 









(Day post tumor implantation)
Number of Days post 
tumor implantation 
at start of treatment
Number of 
Mice Treated
Number of Mice 
at End of Cycle
1st Cycle 13d, 17d, 22d 13 5 2
2nd Cycle 34d, 38d, 42d 34 2 0
Batch B
Treatment Dates
(Day post tumor implantation)
Number of Days post 
tumor implantation 
at start of treatment
Number of 
Mice Treated
Number of Mice 
at End of Cycle
1st Cycle 15d, 19d, 23d 15 4 3
2nd Cycle 36d, 40d, 44d 36 3 3
3rd Cycle 57d, 61d, 65d 57 3 2
4th Cycle 75d, 79d, 83d 75 2 2
5th Cycle 96d, 100d, 104d 96 2 1
6th Cycle 120d, 124d, 128d 120 1 1
7th Cycle 141d, 145d, 149d 141 1 1
Cycles of Drugs Delivered B.
A.
Fig. S2
A. Schematic illustration of our Fitness-adapted approach to preclinical drug testing extracted from
Fig. 1b.
B. Table showing treatment days of ispinesib in Batch A animals (total 2 cycles were delivered), and
Batch B animals (up to 7 cycles were delivered). Our clinical staging system was used to evaluate the
health fitness of the mice daily (5 days/week) to determine further cycles of ispinesib. Ispinesib in-
vivo dosing is 10mg/kg administered intraperitoneally every 4 days for three doses, with the
treatment course repeated around day 21, depending on the mice fitness level. At Stage 3-4, we
would monitor the health of the mice over the next few days before deciding if the mice remain








Red Zone: Starting to get sick



































A. Illustrated staging table on how the animals are staged. Note that not every animal displays the
same pattern of progression in each parameter. The higher stage was used.
B. Pictures demonstrating how additional challenge test (grip test) is performed. Mice were held at
this angle to perform observations on the hind legs as well as the front legs, to determine how the
mouse was moving its limbs in a daily examination. Holding the mouse too near the base of its tail will
cause the examining hand to obstruct the view of the hind leg movements. This grip test manoeuvre
allowed us to observe the mouse doing a front grip onto the grills, and back-kick on the hind legs.
B.
A.
How Grip Test is Performed
STAGING TABLE






































































Relatively more prominent 
nose/cheek bulge, orbital 
tightening leading to narrowed 
eyes
Fig. S4
A. Table showing the day of first symptoms observed, fulfilling Stage 3, 4 and 5 for Batch A animals.
Stage 1 and 2 mice were in optimal health state. This data was used to analyse progression-free and
overall survival as shown in Fig. 1h, i.
Mouse ID














Dates of Treatment Cycle Initiated
(Each Cycle comprised of 3 doses-Dose #1, Dose #2, 
Dose #3)
Untreated 
#1197 25d 25d 27d -
28d 
Died





22d 25d 25d 25d
25d 
Died




#1198 29d 34d 34d 36d
36d 
Sacrificed
#1193 22d 28d 29d -
30d 
Sacrificed









#1301 27d 27d 53d -
54d 
Died
A. Batch A animals
Mouse ID
Date of First Symptom 
(Days after tumor 
implantation)
Date of Stage 3 Date of Stage 4 Date of Stage 5
Date of Death (Days after 
tumor implantation)
Untreated 
#1203 29d 33d 33d -
33d
Sacrificed
#1205 26d 26d 28d -
28d
Sacrificed





















B. Table showing the day of first symptoms observed, fulfilling Stage 3, 4 and 5 for Batch B animals.
Stage 1 and 2 mice were in optimal health state. This data was used to analyse progression-free and
overall survival as shown in Fig. 1h, i.
Batch B animals














A. Top view of cranial cavity showing mice brains in Batch A animals (Treatment Group=5, Control
Group=4). Brains from ispinesib-treated animals (lower 2 panels) were more normal in appearance,
in contrast to untreated control animals (upper panel) which were more necrotic in appearance.





#1198 #1193 #1196 #1200 #1301
Batch A Animals
Fig. S5
B. Hematoxylin & eosin staining of each corresponding mouse brain sectioned in Batch A animals. Red
arrows indicate tumor formation. Some brain specimens have poor quality due to overnight deaths of
animals (#1197, #1311, #1200, #1301). #1301 did not appear to have any visible residual tumor, area
indicated by red arrow demonstrated no tumor cells but a cavitation.
B.
Ispinesib-Treated









A. KIF11 gene expression in relation to GAPDH (housekeeping gene) in patient ATRT tumors of 3
molecular subtypes in Validation Cohort 1 (n=49, Microarray Affymetrix U133plus2.0, GSE7067818).
B. Immunohistochemistry demonstrating KIF11 protein expression on (CHLA-06 xenografts and) patient
ATRT tumors (Validation Cohort 3). Patient 1’s tumor with approximately 10-20% staining (red arrows
indicate mitoses, green arrows indicate apoptotic bodies). KIF11 protein expression co-localized with


































































C. Western blot showing KIF11 protein expression across 7 ATRT cell lines (experimental replicate to Fig.
4d). Single blot, black line delineating section cropped as sample was suboptimal.
D. qRT-PCR replicate showing KIF11 mRNA expression across 7 ATRT cell lines (experimental replicate to
Fig. 3a).
E. Western blot showing increase in apoptotic markers (c-PARP, c-caspase 3) and DNA damage marker (p-
H2AX) with ispinesib treated CHLA-05 ATRT cells, CHLA-06 ATRT cells (replicate of Fig. 4d) and BT-37 ATRT
cells (replicate of Fig. 4d) . Replicate





















































































































A. Additional ATRT cell lines (CHLA-05) were treated with ispinesib and evaluated for cell cycle changes
(Fig. S7A) and apoptosis (Fig. S7B). Cell cycle analysis of CHLA-05 treated with ispinesib (17.7 nM) for 24
h by propidium iodide flow cytometry. CHLA-05 cells treated with ispinesib showed increased percentage
in G2/M phase by 7.4% as compared to DMSO control. This increase was accompanied by the
concomitant decrease in G1 phase by 19% and increase in sub-G1 phase by 11.8%. This result indicated
that ispinesib induced G2/M arrest and subsequent cell death in CHLA-05 cells.
A.
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B. Corresponding CHLA-05 cells were treated with ispinesib and evaluated for cell death and apoptotic
changes. Detection of apoptosis marker in CHLA-05 cells treated with ispinesib (17.7 nM) for 24 and 48 h.
Percentage of secondary necrotic cells (AnV+/PI+ cells) was higher after 48 hrs (23.5%). There was no





























Late Apoptosis Late Apoptosis
24h-Ispinesib-Treated CHLA-05 Cells
48h-Ispinesib-Treated CHLA-05 Cells
Late Apoptosis Late Apoptosis
Early Apoptosis Early Apoptosis
Early Apoptosis Early Apoptosis
24h-DMSO vehicle-Treated CHLA-05 Cells
48h-DMSO vehicle-Treated CHLA-05 Cells
C.
Fig. S7
C. KIF11 is a universal target across all ATRT-subtypes and KIF11-targeting with ispinesib inhibited
proliferation in a panel of 7 ATRT cell lines. IC50 curves of ispinesib on all 7 cell lines (Day 7). Time-
dependent effects of ispinesib on all 7 ATRT cell lines by ispinesib (lowest effective dose for each cell line)
over 13 days.
Fig. S8
A. Nuclear phenotypes observed in ispinesib-treated BT-37 cells (10nM ispinesib).
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Full Length Blot (without ladder)
Original full length blots for Fig. 4d. Aspect ratios were not altered and the cropped images shown in the 
main figures and their corresponding originals were taken at the same exposure level. Only on Microsoft 
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Original full length blots for Fig. 4d. Aspect ratios were not altered and the cropped images shown in the 
main figures and their corresponding originals were taken at the same exposure level. Only on Microsoft 
powerpoint settings, the brightness was adjusted for the main figure clarity.
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Original full length blot for Fig. S6E.
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Ispinesib Treatment
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Original full length blot for Fig. S6E.
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